View allAll Photos Tagged SWITCH
Adding a remote switch to a power strip with cheap parts-- $3 strip from Fry's, <$3 of parts from Discount Builders Supply, and a spare length of cord.
Based on iwilltry's awesome Instructable(s): www.instructables.com/id/Make-your-own-remote-power-switc...
Took Evening Orchid Evangeline and switched her purple wig for the "wind blown too" wig. I think this gives her an evil look.
Membrane Switches from Miller Dial. Order your today.
800-989-3645
www.millerdial.com/products/user-components-and-assemblie...
Aurana Lewis, from the Department of Ecology, and Gabriel Ayala, from Pick A Part in Olympia, WA, discuss how to find and collect anti-lock brake system (ABS) mercury switches from older vehicles.
Switch grass
Panicum 'Prairie Fire'
Kemper - Naumann Experimental Garden
Photo credit: Lisa Francis
Courtesy Missouri Botanical Garden
An ex Warbonnet faces west on an EB power move but with a bit of a twist. If you look above the number boards on the cab you’ll notice a strobe light that is mainly used on locomotives in switching service or remote control operation. While it’s pretty cool, it also is concerning since BNSF has been trying to find any way to get rid of their Dash 9s in the last year or two in favor of more Gevos.
The Off/On switch, Alternating Current jack, A/V jack, and Digital Out port. The pattern for the fan covering was very hard to make , due to its smoothness. Notice the gray pads on the side that the real PS2 has.
Clubbin
The radio afterparty
7 mei 2010
Switch, Hilversum
Eric van Kleef
Hardwell
Norman Soares
PartyXXL.nl
Clubbin
The radio afterparty
7 mei 2010
Switch, Hilversum
Eric van Kleef
Hardwell
Norman Soares
PartyXXL.nl
Photos taken of the new TATE Modern extension on the members preview day. You can read the whole story here:
moderneccentrics.wordpress.com/2016/06/16/tate-modern-swi...
www.msn.com/en-us/money/markets/fda-lays-out-annual-covid...
FDA Lays Out Annual Covid Shot Plan Similar to Flu
(Bloomberg) -- Americans are about to get a clearer idea of how often they’ll roll up their sleeves for Covid-19 shots when advisers to US regulators meet Thursday to discuss an immunization schedule that looks more like the one used for flu.
The plan would have health officials meet each June to review which strains of the virus should be included in Covid shots to be deployed no later than September of the same year, according to documents released by the US Food and Drug Administration ahead of the Jan. 26 meeting.
Experts from around the world convene annually to make predictions about which flu strains will dominate during the upcoming season and, thus, should be targeted by shots. The FDA is looking for a similar coordinated effort to take place at least as often for Covid shots, one of several changes the agency hopes might help simplify the immunization process and encourage more Americans to stay up to date.
Waning immunity from vaccinations and the emergence of new variants every few months has led regulators to recommend variant-targeted boosters, a tactic that so far has been unpopular among Americans and has even split some health experts on costs and benefits. Just weeks after rolling out the updated BA.4 and BA.5 boosters in September, new mutations were rampant. Now, even as the US sees the rise of an immune-evasive variant called XBB.1.5, booster uptake is hovering at about 15%.
“Although the use of the bivalent mRNA boosters is supported by the available evidence, their deployment has been associated with significant implementation complexities,” the FDA said. Switching to one composition for both primary shots and boosters will help streamline the process, according to the agency documents.
Evidence suggests that immunity from prior exposure to the virus along with vaccination will provide enough protection so that most people will need one annual Covid booster, according to the documents. However, young children who might not have been previously exposed and people who are at higher risk for severe disease may need two yearly shots, the FDA said.
“An annual vaccine would be ideal because people would remember, they can do it with other vaccinations like flu and it can last,” Albert Bourla, chief executive officer of Covid vaccine-maker Pfizer Inc., said Jan. 18 in an interview with Bloomberg.
The FDA is still concerned about evasion of vaccine-induced immunity by mutants of the fast-spreading omicron strain, according to the documents. That warrants continued surveillance of variants and also monitoring of the protection previous vaccines provide against new strains.
Pfizer and Moderna Inc. are both working on next-generation vaccines that hold up against mutations and provide longer-lasting protection, but it’s unlikely those will be ready to go into arms anytime soon.
www.news-medical.net/news/20230123/SARS-CoV-2-Omicron-XBB...
SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance
In a recent study posted to bioRxiv* preprint server, researchers at Ohio State University examined the degree of neutralizing antibody (nAb) evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5, CA.3.1, and CH.1.1 subvariants.
Several subvariants have emerged from SARS-CoV-2 Omicron, some showing relatively higher immune evasion, threatening vaccination efficacy. The BQ.1.1 sub-variant was the most prevalent following months of BA.5 predominance in the United States. Nonetheless, it is being quickly replaced by XBB.1.5. The XBB lineage was first detected in India as a recombinant of BA.2.75 and BA.2.10.1.1. Its emergence was alarming since it contained numerous mutations with established immune escape characteristics.
The effectiveness of monoclonal antibodies (mAbs), mono- or bivalent vaccines, and infection-induced immunity were reduced against XBB. The XBB lineage acquired two additional substitutions in the spike, resulting in XBB.1 and XBB.1.5 subvariants, and their impact remains unknown. In addition, the CA.3.1 and CH.1.1 subvariants of Omicron have been notable lately, as they carry the L452R substitution in the spike, previously discovered in the Delta and Omicron BA.4/5 variants.
The study and findings
In the present study, researchers evaluated the spike protein biology of emergent SARS-CoV-2 Omicron subvariants XBB.1.5, CA.3.1, and CH.1.1. First, they assessed the infectivity of spike-pseudotyped lentiviruses in HEK293T-ACE2 cells expressing human angiotensin-converting enzyme 2 (ACE2) and Calu-3 cell line. XBB.1 and XBB.1.5 had higher infectivity, with nearly two-fold increased titers than SARS-CoV-2 D614G in HEK293T-ACE2 cells.
XBB subvariants’ infectivity was not significantly different from that of D614G in this cell line. By contrast, CA.3.1 and CH.1.1 subvariants had nearly 2.5-fold lower infectivity than D614G in Calu-3. Next, the team tested neutralization of these emergent subvariants by sera from 14 healthcare workers (HCWs) boosted with a bivalent vaccine after two-to-four doses of monovalent mRNA vaccine.
Sera were obtained after a median of 66 days post-bivalent vaccination. CA.3.1, CH.1.1, and XBB.1.5 subvariants showed strong resistance to neutralization by sera relative to BA.4/5, with 4.6 to 17.7 times lower nAb titers than BA.4/5. Interestingly, XBB.1.5 had slightly higher nAb titers than its parent lineage (XBB).
Of note, BQ.1.1 showed higher neutralization resistance than any of the XBB subvariants, with 12.8 lower nAb titers than BA.4/5. The CA.3.1 and CH.1.1 subvariants displayed much higher resistance to neutralization by bivalent sera. Next, the neutralization experiments were repeated using sera from HCWs vaccinated thrice with monovalent mRNA vaccines.
Samples were obtained after 2-13 weeks post-vaccination. The mean nAb titers of triple-vaccinated sera against SARS-CoV-2 D614 and Omicron (BA.2 and BA.4/5) were up to 5.6-fold lower than those of bivalent sera. nAb titers were markedly reduced for CA.3.1, CH.1.1, and XBB.1.5 subvariants. Overall, the trends of triple-vaccinated sera in neutralizing subvariants were comparable to those of bivalent sera.
In addition, the team examined the neutralization resistance of subvariants to sera from individuals infected with BA.4/5. They observed potent and near-complete neutralization resistance for CA.3.1, CH.1.1, and XBB.1.1 subvariants, with 2.6 to 4.1-fold lower nAb titers than BA.4/5. Furthermore, the researchers determined fusogenicity, surface expression, and processing of spike proteins of the subvariants.
Reduced syncytia formation was evident for all subvariants relative to D614G. XBB.1 and XBB.1.5 showed no differences in spike fusogenicity compared to XBB. The efficiency of syncytia formation of CA.3.1 and CH.1.1 was lower than BA.2.75.2. XBB subvariants, BQ.1.1, and BA.2.75.2 exhibited higher spike processing than D614G. There were no differences in spike processing for CA.3.1 and CH.1.1 subvariants relative to the parental BA.2.75.2.
Finally, homology modeling of XBB lineage spikes complexed with ACE2 or nAbs was performed. The P486 residue in XBB.1.5 was more hydrophobic than the S486 residue in XBB/XBB.1, resulting in favorable interactions with residues in ACE2, which allows better receptor utilization. The residue 486 is a hotspot for class I nAb recognition, and mutations at this site in XBB subvariants completely abolish interactions with the therapeutic mAb, AZD8895. Mutations at K444 and L452 residues found in CA.3.1 and CH.1.1 also affect interactions with class II nAbs.
Conclusions
Taken together, the findings suggested that bivalent mRNA vaccines induce up to eight times higher nAbs than monovalent vaccines. XBB subvariants, CA.3.1 and CH.1.1, exhibited almost complete escape from neutralization by triple-vaccinated or BA.4/5 infection sera. Moreover, XBB.1.5 did not show enhanced immune evasion relative to BQ.1.1. CA.3.1 and CH.1.1 subvariants consistently showed higher resistance to neutralization than XBB subvariants, warranting continued surveillance and further analyses.
One of the most appreciated features of MVTS II is a
possibility to create a set of routing formulas for customers
with different service levels.
The formulas are used to sort the routing options in the
order of termination priority, and may use over 20 statistical
parameters, including cost, ASR, ACD, ABR, PDD, gateway
load, CPS, etc.